Payment overview · 2025
General Payments
$3,429.61
156 reported records · 37 companies
Healthcare provider profile · identity verified
Ester Bernice Pollard, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CORPUS CHRISTI, TX · NPI 1225002843
Verified facts
What the public records show
CMS Open Payments records show Ester Bernice Pollard, MD received $3,429.61 in general payments during 2025 across 156 reported records.
Novartis Pharmaceuticals Corporation accounted for 9.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 60 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Besremi, Fotivda, Jakafi, Tavalisse, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Venclexta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Aveo Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FOTIVDA as an associated drug or biological on 6531 records involving 3922 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fotivda by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Venclexta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PharmaEssentia USA Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BESREMI as an associated drug or biological on 6276 records involving 3476 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Besremi by this doctor in 2024.
Rigel Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAVALISSE as an associated drug or biological on 3485 records involving 2246 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Tavalisse by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $315.73 | 9.2% | 23 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $286.67 | 8.4% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $253.92 | 7.4% | 7 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.19 | 5.3% | 8 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $173.76 | 5.1% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $173.47 | 5.1% | 7 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $165.41 | 4.8% | 10 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $142.94 | 4.2% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $142.32 | 4.2% | 7 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $133.79 | 3.9% | 6 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $121.52 | 3.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $110.51 | 3.2% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $106.95 | 3.1% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $97.26 | 2.8% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $95.31 | 2.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.78 | 2.6% | 3 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.08 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.22 | 2.1% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $68.71 | 2.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.56 | 1.7% | 3 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $55.67 | 1.6% | 2 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.66 | 1.6% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.12 | 1.4% | 2 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $47.07 | 1.4% | 2 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $45.09 | 1.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $43.17 | 1.3% | 2 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $39.44 | 1.1% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $31.39 | 0.9% | 1 | 2025 |
| Amicus Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.70 | 0.9% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $27.07 | 0.8% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.14 | 0.8% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $21.74 | 0.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.33 | 0.6% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.25 | 0.6% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.01 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.97 | 0.6% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $16.69 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,264.35 | 153 |
| Education | $165.26 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $286.67 | 15 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $181.19 | 8 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $181.19 | 8 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $181.19 | 8 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $173.76 | 6 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $165.41 | 10 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Biological, Drug | ABBVIE INC., Genentech USA, Inc. | $143.53 | 5 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $142.94 | 10 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $134.61 | 6 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $128.15 | 8 | 2025 |
Source payment records
|
|||||
| KOSELUGO Normalized: koselugo |
Drug | Alexion Pharmaceuticals, Inc. | $121.52 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $120.26 | 7 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $110.51 | 4 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $88.45 | 5 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $83.11 | 7 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $79.08 | 2 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $71.22 | 4 | 2025 |
Source payment records
|
|||||
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $70.56 | 3 | 2025 |
Source payment records
|
|||||
| Tecentriq Hybreza Normalized: tecentriq hybreza |
Biological | Genentech USA, Inc. | $64.74 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $57.56 | 3 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $57.56 | 3 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $57.25 | 2 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $55.94 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $55.67 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $55.56 | 2 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $53.66 | 2 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $47.07 | 2 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | E.R. Squibb & Sons, L.L.C. | $45.92 | 2 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $43.17 | 2 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $40.24 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $40.01 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $39.44 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $34.91 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $31.16 | 1 | 2025 |
Source payment records
|
|||||
| WAYRILZ Normalized: wayrilz |
Drug | GENZYME CORPORATION | $30.83 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $30.17 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| ENJAYMO Normalized: enjaymo |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| XALKORI Normalized: xalkori |
Drug | ARRAY BIOPHARMA INC | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $21.74 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| OGSIVEO Normalized: ogsiveo |
Drug | SpringWorks Therapeutics, Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $16.02 | 3 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $7.85 | 1 | 2025 |
Source payment records
|
|||||
| Xospata Normalized: xospata |
Drug | Astellas Pharma US Inc | $2.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BESREMI besremi |
2025 | Besremi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FOTIVDA fotivda |
2025 | Fotivda | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAVALISSE tavalisse |
2025 | Tavalisse | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Aveo Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | FOTIVDA open payments reported associated product |
CMS Open Payments — General Payments 6531 supporting records · 3922 recipient NPIs · example record 1199896322 |
Fotivda · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PharmaEssentia USA Corporation Exact reporting entity; no affiliate inference |
2025 | BESREMI open payments reported associated product |
CMS Open Payments — General Payments 6276 supporting records · 3476 recipient NPIs · example record 1246822425 |
Besremi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Rigel Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | TAVALISSE open payments reported associated product |
CMS Open Payments — General Payments 3485 supporting records · 2246 recipient NPIs · example record 1247366339 |
Tavalisse · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 947 | 112 |
| Alprazolam | Alprazolam | 366 | 52 |
| Prednisone | Prednisone | 146 | 58 |
| Tramadol Hcl | Tramadol Hcl | 120 | 21 |
| Gabapentin | Gabapentin | 110 | 23 |
| Azithromycin | Azithromycin | 109 | 58 |
| Ibuprofen | Ibuprofen | 91 | 27 |
| Fentanyl | Fentanyl | 84 | 14 |
| Potassium Chloride | Potassium Chloride | 77 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 31 |
| Temazepam | Temazepam | 74 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 37 |
| Furosemide | Furosemide | 64 | 20 |
| Hydromorphone Hcl | Hydromorphone Hcl | 62 | 11 |
| Anastrozole | Anastrozole | 60 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 57 | 17 |
| Hydroxyurea | Hydroxyurea | 57 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 18 |
| Megestrol Acetate | Megestrol Acetate | 48 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Sucralfate | Sucralfate | 44 | 23 |
| Methadone Hcl | Methadone Hcl | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 18 |
| Losartan Potassium | Losartan Potassium | 40 | 13 |
| Promacta | Eltrombopag Olamine | 38 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 35 | 17 |
| Lisinopril | Lisinopril | 35 | suppressed |
| Eliquis | Apixaban | 33 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 11 |
| Venclexta | Venetoclax | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 31 | suppressed |
| Tasigna | Nilotinib Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Tavalisse | Fostamatinib Disodium | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 16 |
| Morphine Sulfate | Morphine Sulfate | 27 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 14 |
| Clonidine | Clonidine | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 14 |
| Lactulose | Lactulose | 25 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | 12 |
| Zarxio | Filgrastim-Sndz | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Folic Acid | Folic Acid | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Constulose | Lactulose | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Allopurinol | Allopurinol | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Fotivda | Tivozanib Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Besremi | Ropeginterferon Alfa-2b-Njft | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,429.61 · 156 records | Novartis Pharmaceuticals Corporation | BESREMI, BRAFTOVI, CALQUENCE, DARZALEX, DATROWAY, ENJAYMO, Empaveli, Enhertu, FOTIVDA, Fabhalta, GOMEKLI, Gavreto, ICLUSIG, JAKAFI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, KOSELUGO, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, MONOFERRIC, NERLYNX, Nubeqa, OGSIVEO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, PLUVICTO, PYRUKYND, QINLOCK, REBLOZYL, ROMVIMZA, RYBREVANT, RYTELO, Rezlidhia, SCEMBLIX, SYNCHROMEDII, TAGRISSO, TALVEY, TALZENNA, TAVALISSE, TECVAYLI, TGCT, Tecentriq, Tecentriq Hybreza, Trodelvy, VENCLEXTA, Vonjo, Vyloy, WAYRILZ, XALKORI, XPOVIO, XTANDI, Xofigo, Xospata, ZYNLONTA, Zoladex | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Besremi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error